DDrare: Database of Drug Development for Rare Diseases

Opc-6535(tetomilast) (DrugBank: Tetomilast)

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00317369 (ClinicalTrials.gov)	May 2006	21/4/2006	A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease	A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease	Crohn Disease	Drug: OPC-6535(Tetomilast)	Otsuka Pharmaceutical Co., Ltd.	NULL	Terminated	16 Years	65 Years	Both	60	Phase 2	Japan

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00317356 (ClinicalTrials.gov)	May 2006	21/4/2006	A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis	A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis	Colitis, Ulcerative	Drug: OPC-6535(Tetomilast)	Otsuka Pharmaceutical Co., Ltd.	NULL	Terminated	18 Years	65 Years	Both	160	Phase 2	Japan